How To Get Pregnant With PCOS

Home » fertilPEDIA » How To Get Pregnant With PCOS

By



Attention: You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

This content is WordProof timestamped

How to Get Pregnant with PCOS

Main article: Polycystic Ovary Syndrome Overview

Updated: 17-October-2024

How to get pregnant with PCOS

Women with PCOS can become pregnant naturally or with medical assistance. Up to 70% of women with PCOS are diagnosed with infertility.1,2 However at least 1 in 3 women with PCOS are fertile.3

For this reason, doctors usually recommend women try to conceive naturally for 6+ months if their cycles are sometimes regular or there is room for improvement (lifestyle modification).

However, if the couple are still unsuccessful after 6 to 12 months, the doctor will recommend medically assisted reproduction.

Natural Conception with PCOS

Many women with PCOS are able to get pregnant naturally however this does take longer than normal fertile couples.

Regular menstrual cycles ensures good ovulation, sperm friendly cervical mucus and a receptive endometrium.

Even though women with irregular cycles can still get pregnant, especially if they’re tracking ovulation, this is not usually recommended on its own.

Read More:

Instead, experts recommend women trying to get pregnant naturally with PCOS consider:

  • Exercise
  • Diet
  • Losing weight
  • Minimize stress
  • Eliminate endocrine disrupting chemicals
  • Fertility awareness-based methods (FABM)
  • Supplements

Of course this is still only possible with good sperm quality. Research suggests men need to have average sperm motility or TPMSC (total progressive motile sperm count) given women with PCOS have suboptimal cervical mucus.4,5

After successful fertilization, the embryo is then ready for implantation. However this can also be difficult for some women with PCOS due to endometrial dysfunction.6 These women fail to get pregnant naturally after 6 to 12 months of consistent ovulation or experience early miscarriages. In such cases, medical assistance is required.

Exercise

Exercise is a first-line treatment option for women with PCOS.7 Exercise (via irisin) decreases oxidative stress and inflammation, which in turn improves ovary function, hormone levels and insulin resistance.8,9,10

Exercise is reportedly more effective than diet at improving insulin levels.

Source: Jurczewska J, et al. (2023)

However not all exercise is the same. In a large comparison study, high-intensity interval training (HIIT) significantly improved sex hormone-binding globulin (SHBG), free androgen index (FAI), insulin sensitivity and menstrual cycles more than medium-intensity interval training (MICT) among overweight women with PCOS.11 Patten et al. reported that HIIT participants were 7.8 times more likely to report improvements in their menstrual cycle.10 However, only low volume HIIT appears to improve fertility.12

References

  1. Tay C H, et al. (2023). High prevalence of medical conditions and unhealthy lifestyle behaviours in women with PCOS during preconception: findings from the Australian Longitudinal Study on Women’s Health. https://academic.oup.com/humrep/article/38/11/2267/7281033 ↩︎
  2. Joham A E, et al. (2015). Prevalence of Infertility and Use of Fertility Treatment in Women with Polycystic Ovary Syndrome: Data from a Large Community-Based Cohort Study. https://www.liebertpub.com/doi/10.1089/jwh.2014.5000 ↩︎
  3. Boyle J and Teede H, (2012). Polycystic ovary syndrome – an update. https://pubmed.ncbi.nlm.nih.gov/23210095/ ↩︎
  4. Shamim N, et al. (2012). The elasticity of cervical-vaginal secretions is abnormal in polycystic ovary syndrome: Case report of five PCOS women. https://journals.lww.com/indjem/fulltext/2012/16060/the_elasticity_of_cervical_vaginal_secretions_is.29.aspx ↩︎
  5. Vigil P, et al. (2009). Scanning electron and light microscopy study of the cervical mucus in women with polycystic ovary syndrome. https://academic.oup.com/jmicro/article-abstract/58/1/21/1988760 ↩︎
  6. Matsuyama S, et al. (2024). Implantation and Decidualization in PCOS: Unraveling the Complexities of Pregnancy. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10816633/ ↩︎
  7. Teede H J, et al. (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. https://academic.oup.com/humrep/article/38/9/1655/7241786 ↩︎
  8. Babaei Bonab S and Parvaneh M, (2023). Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. https://www.sciencedirect.com/science/article/pii/S0765159723000758 ↩︎
  9. Weng Y, et al. (2023). Exercise-induced irisin improves follicular dysfunction by inhibiting IRE1α-TXNIP/ROS-NLRP3 pathway in PCOS. https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-023-01242-x ↩︎
  10. Li C G, et al. (2024). Effect of irisin on ovarian phosphatidylinositol-3-kinase/protein kinase B signaling pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathways of rats with polycystic ovary syndrome. https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/jog.16076 ↩︎
  11. Patten R K, et al. (2022). High-intensity training elicits greater improvements in cardio-metabolic and reproductive outcomes than moderate-intensity training in women with polycystic ovary syndrome: a randomized clinical trial. https://academic.oup.com/humrep/article/37/5/1018/6552984 ↩︎
  12. Kiel I A, et al. (2022). High-Intensity Interval Training in Polycystic Ovary Syndrome: A Two-Center, Three-Armed Randomized Controlled Trial. https://journals.lww.com/acsm-msse/fulltext/2022/05000/high_intensity_interval_training_in_polycystic.2.aspx ↩︎
  13. Mei S, et al. (2022). Mediterranean Diet Combined With a Low-Carbohydrate Dietary Pattern in the Treatment of Overweight Polycystic Ovary Syndrome Patients. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.876620/full ↩︎
  14. Ravisankar S, et al. (2022). Long-term Hyperandrogenemia and/or Western-style Diet in Rhesus Macaque Females Impairs Preimplantation Embryogenesis. https://academic.oup.com/endo/article/163/4/bqac019/6534477 ↩︎
  15. Łagowska K and Pieczyńska J M, (2022). Not only diet quality and physical activity but also snacking and skipping meals could be related with menstrual disorders in PCOS. https://www.tandfonline.com/doi/full/10.1080/03630242.2022.2106529 ↩︎
  16. Li C, et al. (2021). Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02817-2 ↩︎
  17. Jakubowicz D, et al. (2013). Effects of caloric intake timing on insulin resistance and hyperandrogenism in lean women with polycystic ovary syndrome. https://portlandpress.com/clinsci/article-abstract/125/9/423/69160/Effects-of-caloric-intake-timing-on-insulin ↩︎
  18. Kiddy D S, et al. (1992). Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.1992.tb02909.x ↩︎
  19. Luo E, et al. (2021). Serum Anti-Müllerian Hormone Levels Were Negatively Associated With Body Fat Percentage in PCOS Patients. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.659717/full ↩︎
  20. Dietz de Loos A, et al. (2021). Antimüllerian hormone to determine polycystic ovarian morphology. https://www.fertstert.org/article/S0015-0282(21)00447-7/fulltext ↩︎
  21. Kataoka J, et al. (2022). Circulating Anti-Müllerian hormone in a cohort-study of women with severe obesity with and without polycystic ovary syndrome and the effect of a one-year weight loss intervention. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617381/ ↩︎
  22. Zhang Q, et al. (2023). Effect of obstructive sleep apnea on in vitro fertilization outcomes in women with polycystic ovary syndrome. https://jcsm.aasm.org/doi/full/10.5664/jcsm.10780 ↩︎
  23. Haase C L, et al. (2023). Association between body mass index, weight loss and the chance of pregnancy in women with polycystic ovary syndrome and overweight or obesity: a retrospective cohort study in the UK. https://academic.oup.com/humrep/article/38/3/471/6986989 ↩︎
  24. Szczuko M, et al. (2021). A Properly Balanced Reduction Diet and/or Supplementation Solve the Problem with the Deficiency of These Vitamins Soluble in Water in Patients with PCOS. https://www.mdpi.com/2072-6643/13/3/746 ↩︎
  25. Mohammadi S, et al. (2023). Effects of eight-week high-intensity interval training on some metabolic, hormonal and cardiovascular indices in women with PCOS: a randomized controlled trail. https://bmcsportsscimedrehabil.biomedcentral.com/articles/10.1186/s13102-023-00653-z ↩︎
  26. Jiskoot G, et al. (2022). Lifestyle treatment in women with polycystic ovary syndrome: predictors of weight loss and dropout. https://onlinelibrary.wiley.com/doi/10.1002/brb3.2621 ↩︎
  27. Hager M, et al. (2023). Stress and polycystic ovarian morphology in functional hypothalamic amenorrhea: a retrospective cohort study. https://rbej.biomedcentral.com/articles/10.1186/s12958-023-01095-5 ↩︎
  28. Prior J C, et al. (2022). Adaptive, reversible, hypothalamic reproductive suppression: More than functional hypothalamic amenorrhea. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.893889/ ↩︎
  29. Marschalek M L, et al. (2023). A case-control study about markers of stress in normal-/overweight women with polycystic ovary syndrome and in controls. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1173422/ ↩︎
  30. Dumesic D A, et al. (2023). Interplay of Cortisol, Testosterone, and Abdominal Fat Mass in Normal-weight Women With Polycystic Ovary Syndrome. https://academic.oup.com/jes/article/7/8/bvad079/7191792 ↩︎
  31. Kechagias K S, et al. (2020). Bisphenol-A and polycystic ovary syndrome: a review of the literature. https://www.degruyter.com/document/doi/10.1515/reveh-2020-0032/html ↩︎
  32. Jurewicz J, et al. (2020). Serum bisphenol A analogues in women diagnosed with the polycystic ovary syndrome – is there an association? https://www.sciencedirect.com/science/article/pii/S0269749120366513 ↩︎
  33. Yenigül N N, et al. (2021). The effect of plastic bottled water consumption on outcomes of ICSI cycles undertaken for unexplained infertility. https://www.rbmojournal.com/article/S1472-6483(21)00186-3/ ↩︎
  34. Lin M, et al. (2021). Bisphenol A promotes autophagy in ovarian granulosa cells by inducing AMPK/mTOR/ULK1 signalling pathway. https://www.sciencedirect.com/science/article/pii/S0160412020322534 ↩︎
  35. Yang Q, et al. (2015). Association of serum levels of typical organic pollutants with polycystic ovary syndrome (PCOS): a case–control study. https://academic.oup.com/humrep/article/30/8/1964/950085 ↩︎
  36. Vagi S J, et al. (2014). Exploring the potential association between brominated diphenyl ethers, polychlorinated biphenyls, organochlorine pesticides, perfluorinated compounds, phthalates, and bisphenol a in polycystic ovary syndrome: a case–control study. https://bmcendocrdisord.biomedcentral.com/articles/10.1186/1472-6823-14-86 ↩︎
  37. Kunitomi C, et al. (2021). Induction of aryl hydrocarbon receptor in granulosa cells by endoplasmic reticulum stress contributes to pathology of polycystic ovary syndrome. https://academic.oup.com/molehr/article/27/3/gaab003/6119640 ↩︎
  38. Li J, et al. (2018). Effect of exposure to second-hand smoke from husbands on biochemical hyperandrogenism, metabolic syndrome and conception rates in women with polycystic ovary syndrome undergoing ovulation induction. https://academic.oup.com/humrep/article/33/4/617/4877148 ↩︎
  39. Xirofotos D, et al. (2016). The amount and duration of smoking is associated with aggravation of hormone and biochemical profile in women with PCOS. https://www.tandfonline.com/doi/full/10.3109/09513590.2015.1101440 ↩︎
  40. Cupisti S, et al. (2009). Smoking is associated with increased free testosterone and fasting insulin levels in women with polycystic ovary syndrome, resulting in aggravated insulin resistance. https://www.fertstert.org/article/S0015-0282(09)00632-3/fulltext ↩︎
  41. Gunning M N, et al. (2022). Predicting pregnancy chances leading to term live birth in oligo/anovulatory women diagnosed with PCOS. https://www.rbmojournal.com/article/S1472-6483(22)00752-0/ ↩︎
  42. Li J, et al. (2018). Effect of exposure to second-hand smoke from husbands on biochemical hyperandrogenism, metabolic syndrome and conception rates in women with polycystic ovary syndrome undergoing ovulation induction. https://academic.oup.com/humrep/article/33/4/617/4877148 ↩︎
  43. Duane M, et al. (2022). Fertility Awareness-Based Methods for Women’s Health and Family Planning. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171018/ ↩︎
  44. Stachowska A, et al. (2024). Usefulness of the Sympto-Thermal Method with Standardized Cervical Mucus Assessment (InVivo Method) for Evaluating the Monthly Cycle in Women with Polycystic Ovary Syndrome (PCOS). https://www.mdpi.com/2227-9032/12/11/1108 ↩︎
  45. Kicińska A M, et al. (2023). Successful Implementation of Menstrual Cycle Biomarkers in the Treatment of Infertility in Polycystic Ovary Syndrome—Case Report. https://www.mdpi.com/2227-9032/11/4/616 ↩︎
  46. Unfer V, et al. (2020). Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS. https://www.mdpi.com/1422-0067/21/19/7157 ↩︎
  47. Fedeli V, et al. (2023). The Role of Inositols in the Hyperandrogenic Phenotypes of PCOS: A Re-Reading of Larner’s Results. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093919/ ↩︎
  48. Cianci A and Vitale S G, (2022). D-Chiro-inositol and PCOS: between myth and reality. The never-ending story. https://www.tandfonline.com/doi/full/10.1080/09637486.2022.2029830 ↩︎
  49. Facchinetti F, et al. (2019). Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. https://www.tandfonline.com/doi/full/10.1080/09513590.2018.1540578 ↩︎
  50. Pizzo A, et al. (2013). Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS. https://www.tandfonline.com/doi/full/10.3109/09513590.2013.860120 ↩︎
  51. Constantino D, et al. (2009). Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. https://pubmed.ncbi.nlm.nih.gov/19499845/ ↩︎
  52. Rajasekaran K, et al. (2021). Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study. https://www.tandfonline.com/doi/full/10.1080/09513590.2021.1981282 ↩︎
  53. Unfer V, et al. (2023). Treatment with Myo-Inositol Does Not Improve the Clinical Features in All PCOS Phenotypes. https://www.mdpi.com/2227-9059/11/6/1759 ↩︎
  54. Kamenov Z, et al. (2023). Comparing the Efficacy of Myo-Inositol Plus α-Lactalbumin vs. Myo-Inositol Alone on Reproductive and Metabolic Disturbances of Polycystic Ovary Syndrome. https://www.mdpi.com/2218-1989/13/6/717 ↩︎
  55. Hernandez Marin I, et al. (2021). A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients. https://www.europeanreview.org/article/25743 ↩︎
  56. Fruzzetti F, et al. (2019).Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome. https://www.tandfonline.com/doi/full/10.1080/09513590.2019.1640673 ↩︎
  57. Genazzani A D, et al. (2019). Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. https://www.tandfonline.com/doi/full/10.1080/09513590.2019.1640200 ↩︎
  58. Monastra G, et al. (2018). Alpha-lactalbumin Effect on Myo-inositol Intestinal Absorption: In vivo and In vitro. https://www.eurekaselect.com/article/90292 ↩︎
  59. Oliva M M, et al. (2018). Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-018-0411-2 ↩︎
  60. De Grazia S, et al. (2012). Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects. https://www.tandfonline.com/doi/full/10.1517/17425247.2012.701616 ↩︎
  61. Benvenga S, (2012). (Soft) capsules of wisdom: preventing myo-inositol malabsorption caused by coffee. https://www.tandfonline.com/doi/full/10.1517/17425247.2012.719495 ↩︎
  62. Mishra N, et al. (2022). Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study. https://www.cureus.com/articles/77796-study-on-the-effect-of-berberine-myoinositol-and-metformin-in-women-with-polycystic-ovary-syndrome-a-prospective-randomised-study ↩︎
  63. Wei W, et al. (2011). A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. https://academic.oup.com/ejendo/article-abstract/166/1/99/6659259 ↩︎
  64. Orio F, et al. (2013). Berberine improves reproductive features in obese Caucasian women with polycystic ovary syndrome independently of changes of insulin sensitivity. https://www.sciencedirect.com/science/article/pii/S2212826313000742 ↩︎
  65. Wu X K, et al. (2016). Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome. https://www.fertstert.org/article/S0015-0282(16)61289-X/ ↩︎
  66. Moreira E S, et al. (2022). The short-term effects of berberine in the liver: Narrow margins between benefits and toxicity. https://www.sciencedirect.com/science/article/pii/S0378427422009845 ↩︎
  67. Monastra G, et al. (2018). Vitamin D: a steroid hormone with progesterone-like activity. https://www.europeanreview.org/article/14845 ↩︎
  68. Drincic A T, et al. (2012). Volumetric Dilution, Rather Than Sequestration Best Explains the Low Vitamin D Status of Obesity. https://onlinelibrary.wiley.com/doi/10.1038/oby.2011.404 ↩︎
  69. Al-Bayyari N, et al. (2020). Androgens and hirsutism score of overweight women with polycystic ovary syndrome improved after vitamin D treatment: A randomized placebo controlled clinical trial. https://www.clinicalnutritionjournal.com/article/S0261-5614(20)30496-9/abstract ↩︎
  70. Pal L, et al. (2016). Vitamin D Status Relates to Reproductive Outcome in Women With Polycystic Ovary Syndrome: Secondary Analysis of a Multicenter Randomized Controlled Trial. https://academic.oup.com/jcem/article/101/8/3027/2835026 ↩︎
  71. Piao C, et al. (2024). Effect of vitamin D on pregnancy in women with polycystic ovary syndrome: retrospective and prospective studies. https://www.rbmojournal.com/article/S1472-6483(24)00098-1/abstract ↩︎
  72. Safari H, et al. (2022). Vitamin D and calcium, together and separately, play roles in female reproductive performance. https://www.nature.com/articles/s41598-022-14708-7 ↩︎
  73. Kadoura S, et al. (2019). Effect of Calcium and Vitamin D Supplements as an Adjuvant Therapy to Metformin on Menstrual Cycle Abnormalities, Hormonal Profile, and IGF-1 System in Polycystic Ovary Syndrome Patients: A Randomized, Placebo-Controlled Clinical Trial. https://onlinelibrary.wiley.com/doi/10.1155/2019/9680390 ↩︎
  74. Tehrani H G, et al. (2014). The effect of calcium and vitamin D supplementation on menstrual cycle, body mass index and hyperandrogenism state of women with poly cystic ovarian syndrome. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268197/ ↩︎
  75. Thys-Jacobs S, et al. (1999). Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. https://www.sciencedirect.com/science/article/pii/S0039128X99000124 ↩︎
  76. Sert Z S, et al. (2022). Effect of calcium and vitamin D supplementation on the clinical, hormonal, and metabolic profile in non-obese women with polycystic ovary syndrome. https://link.springer.com/article/10.1007/s11845-021-02899-3 ↩︎
  77. Rondanelli M, et al. (2014). Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena. https://link.springer.com/article/10.1007/s00404-014-3433-z ↩︎
  78. Nadjarzadeh A, et al. (2013). The effect of omega-3 supplementation on androgen profile and menstrual status in women with polycystic ovary syndrome: A randomized clinical trial. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941370/ ↩︎
  79. Khani B, et al. (2017). Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome. https://journals.lww.com/jrms/fulltext/2017/22000/omega_3_supplementation_effects_on_polycystic.64.aspx ↩︎
  80. Bahramian H, et al. (2023). Effects of single-dose and co-supplementation of vitamin D and omega-3 on metabolic profile in women with polycystic ovary syndrome: An RCT. https://knepublishing.com/index.php/ijrm/article/view/13889 ↩︎
  81. Trop-Steinberg S, et al. (2023). Omega-3 Intake Improves Clinical Pregnancy Rate in Polycystic Ovary Syndrome Patients: A Double-Blind, Randomized Study. https://pubmed.ncbi.nlm.nih.gov/36841983/ ↩︎
  82. Tsuji A, et al. (2017). Effects of Mild and Severe Vitamin B1 Deficiencies on the Meiotic Maturation of Mice Oocytes. https://journals.sagepub.com/doi/10.1177/1178638817693824 ↩︎
  83. Szczuko M, et al. (2021). A Properly Balanced Reduction Diet and/or Supplementation Solve the Problem with the Deficiency of These Vitamins Soluble in Water in Patients with PCOS. https://www.mdpi.com/2072-6643/13/3/746 ↩︎
  84. Moti M, et al. (2024). The Effects of Thiamine Supplementation on General Health and Infertility Treatment Outcomes in Women with Polycystic Ovary Syndrome: A Triple-Blinded Randomized Placebo-Controlled Clinical Trial. https://www.ijfs.ir/article_706404.html ↩︎
  85. Shah M, et al. (2023). Effect of quercetin on steroidogenesis and folliculogenesis in ovary of mice with experimentally-induced polycystic ovarian syndrome. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1153289/full ↩︎
  86. Rezvan N, et al. (2018). Effects of Quercetin on Adiponectin-Mediated Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Double-Blind Clinical Trial. https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0042-118705 ↩︎
  87. Rezvan N, et al. (2017). Effects of Quercetin on Adiponectin-Mediated Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Double-Blind Clinical Trial. https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0042-118705 ↩︎
  88. Vaez S, et al. (2022). Quercetin and polycystic ovary syndrome; inflammation, hormonal parameters and pregnancy outcome: A randomized clinical trial. https://onlinelibrary.wiley.com/doi/10.1111/aji.13644 ↩︎
  89. Cai S, et al. (2020). One Carbon Metabolism and Mammalian Pregnancy Outcomes. https://onlinelibrary.wiley.com/doi/abs/10.1002/mnfr.202000734 ↩︎
  90. Kazerooni T, et al. (2008). Effect of folic acid in women with and without insulin resistance who have hyperhomocysteinemic polycystic ovary syndrome. https://obgyn.onlinelibrary.wiley.com/doi/10.1016/j.ijgo.2007.10.024 ↩︎
  91. Guzelmeric K, et al. (2007). Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. https://www.tandfonline.com/doi/full/10.1080/09513590701554306 ↩︎
  92. Ganie M A, et al. (2024). Impact of Prevalent Dietary Pattern on Serum Vitamin B12 Status and Its Association With Inflammation Among Reproductive Age Women. https://onlinelibrary.wiley.com/doi/10.1002/mnfr.202300315 ↩︎
  93. Kaye A, et al. (2020). Folic Acid Supplementation in Patients with Elevated Homocysteine Levels. https://link.springer.com/article/10.1007/s12325-020-01474-z ↩︎
  94. Schiuma N, et al. (2019). Micronutrients in support to the one carbon cycle for the modulation of blood fasting homocysteine in PCOS women. https://link.springer.com/article/10.1007/s40618-019-01163-x ↩︎
  95. Lai X L, et al. (2023). Zinc deficiency compromises the maturational competence of porcine oocyte by inducing mitophagy and apoptosis. https://www.sciencedirect.com/science/article/pii/S0147651323000970 ↩︎
  96. Khademi Z, et al. (2023). Association Between Selenium and Circulating Adipokine Levels in Patients with Polycystic Ovary Syndrome. https://link.springer.com/article/10.1007/s12011-023-03935-2 ↩︎
  97. Amirkhizi F, et al. (2023). Association of Serum Selenium and Selenoprotein P with Oxidative Stress Biomarkers in Patients with Polycystic Ovary Syndrome. https://link.springer.com/article/10.1007/s12011-023-03747-4 ↩︎
  98. Coskun A, et al. (2013). Plasma selenium levels in Turkish women with polycystic ovary syndrome. https://www.ejog.org/article/S0301-2115(13)00064-X/abstract ↩︎
  99. Razavi M, et al. (2016). Selenium Supplementation and the Effects on Reproductive Outcomes, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome. https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0035-1559604 ↩︎
  100. Poormoosavi S M, et al. (2021). The effect of follicular fluid selenium concentration on oocyte maturation in women with polycystic ovary syndrome undergoing in vitro fertilization/Intracytoplasmic sperm injection: A cross-sectional study. https://knepublishing.com/index.php/ijrm/article/view/9616 ↩︎
  101. Kazemi M, et al. (2021). Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome. https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-021-00849-2 ↩︎
  102. Galano A, et al. (2011). Melatonin as a natural ally against oxidative stress: a physicochemical examination. https://onlinelibrary.wiley.com/doi/10.1111/j.1600-079X.2011.00916.x ↩︎
  103. Xie F, et al. (2021). Melatonin ameliorates ovarian dysfunction by regulating autophagy in PCOS via the PI3K-Akt pathway. https://rep.bioscientifica.com/view/journals/rep/162/1/REP-20-0643.xml ↩︎
  104. Tanavde V and Maitra A, (2011). In Vitro Modulation of Steroidogenesis and Gene Expression by Melatonin: A Study with Porcine Antral Follicles. https://www.tandfonline.com/doi/full/10.1081/ERC-120026946 ↩︎
  105. Jamilian M, et al. (2019). Effects of Melatonin Supplementation on Hormonal, Inflammatory, Genetic, and Oxidative Stress Parameters in Women With Polycystic Ovary Syndrome. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00273/full ↩︎
  106. Tagliaferri V, et al. (2017). Melatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women With PCOS: A Pilot Study. https://link.springer.com/article/10.1177/1933719117711262 ↩︎
  107. Pilehvari S, et al. (2023). The Boosting Effects of Melatonin on the In Vitro Fertilization (IVF) of Women with Polycystic Ovary Syndrome. https://cmj.ac.kr/DOIx.php?id=10.4068/cmj.2023.59.3.188 ↩︎
  108. Evans A T, et al. 2023. Overnight Melatonin Concentration and Sleep Quality Are Associated with the Clinical Features of Polycystic Ovary Syndrome. https://www.mdpi.com/2227-9059/11/10/2763 ↩︎
  109. Luo Xi, et al. (2021). Associations of Serum Magnesium With Insulin Resistance and Testosterone in Women With Polycystic Ovary Syndrome. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.683040/full ↩︎
  110. Szczuko M, et al. (2016). Quantitative assessment of nutrition in patients with polycystic ovary syndrome (PCOS). https://pubmed.ncbi.nlm.nih.gov/27925712/ ↩︎
  111. Gholizadeh-Moghaddam M, et al. (2022). Effect of magnesium supplementation in improving hyperandrogenism, hirsutism, and sleep quality in women with polycystic ovary syndrome: A randomized, placebo-controlled clinical trial. https://onlinelibrary.wiley.com/doi/10.1002/hsr2.1013 ↩︎
  112. Hamilton K P, et al. (2019). Insulin Resistance and Serum Magnesium Concentrations among Women with Polycystic Ovary Syndrome. https://cdn.nutrition.org/article/S2475-2991(22)13080-5/fulltext ↩︎
  113. Alizadeh M, et al. (2021). Metabolic and hormonal effects of melatonin and/or magnesium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/s12986-021-00586-9 ↩︎
  114. Mousavi R, et al. (2021). Effects of Melatonin and/or Magnesium Supplementation on Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. https://link.springer.com/article/10.1007/s12011-021-02725-y ↩︎
  115. Antaki R, et al. (2011). An Algorithm Combining Ultrasound Monitoring and Urinary Luteinizing Hormone Testing: A Novel Approach for Intrauterine Insemination Timing. https://www.sciencedirect.com/science/article/abs/pii/S1701216316351106 ↩︎
  116. Amer S A, et al. (2017). Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome. https://academic.oup.com/humrep/article/32/8/1631/3897382 ↩︎
  117. Legro R S, et al. (2014). Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. https://www.nejm.org/doi/10.1056/NEJMoa1313517 ↩︎
  118. Sakar M N and Oglak S C, (2020). Letrozole is superior to clomiphene citrate in ovulation induction in patients with polycystic ovary syndrome. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674913/ ↩︎
  119. Arya S, et al. (2021). Metabolic syndrome in obesity: treatment success and adverse pregnancy outcomes with ovulation induction in polycystic ovary syndrome. https://www.ajog.org/article/S0002-9378(21)00447-6/abstract ↩︎
  120. Shi L, et al. (2022). Effect of different timing of letrozole initiation on pregnancy outcome in polycystic ovary syndrome. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.1059609 ↩︎
  121. Khurana A, et al. (2022). Prevalence of Polycystic Ovarian Syndrome, Phenotypes and their Ovulation Response to Sequential Letrozole Dose Escalation among Infertile Women at a Tertiary Care Centre in Southern India. https://journals.lww.com/jhrs/fulltext/2022/15010/prevalence_of_polycystic_ovarian_syndrome,.7.aspx ↩︎
  122. Xia T T, et al. (2023). Comparison of Three Ovulation Induction Therapies for Patients With Polycystic Ovary Syndrome and Infertility. https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.2318 ↩︎
  123. Guan H J, et al. (2021). Predictors of pregnancy after intrauterine insemination in women with polycystic ovary syndrome. https://journals.sagepub.com/doi/10.1177/03000605211018600 ↩︎
  124. Dai X, et al. (2023). Ovulation induction using sequential letrozole/gonadotrophin in infertile women with PCOS: a randomized controlled trial. https://www.rbmojournal.com/article/S1472-6483(22)00537-5/fulltext ↩︎
  125. Zhang X, et al. (2021). Application of Pulsed Rhythmic Drug Administration to Ovulation Induction Therapy in PCOS Patients with Clomiphene-Resistance: a Retrospective Research. https://link.springer.com/article/10.1007/s43032-021-00639-7 ↩︎
  126. Sakar M N and Oğlak S C, (2020). Comparison of the efficacy of letrozole stair-step protocol with clomiphene citrate stair-step protocol in the management of clomiphene citrate-resistant polycystic ovary syndrome patients. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/jog.14936 ↩︎
  127. Gysler M, et al. (1982). A decade’s experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. https://www.sciencedirect.com/science/article/pii/S0015028216460334 ↩︎
  128. Meun C, et al. (2022). The influence of ethnicity on outcomes of ovulation induction with clomifene citrate in women with PCOS. https://www.rbmojournal.com/article/S1472-6483(21)00614-3/fulltext ↩︎
  129. Wang J, et al. (2021). Relationship between proinflammatory cytokines and clomiphene resistance in patients with polycystic ovary syndrome. https://apm.amegroups.org/article/view/84296/html ↩︎
  130. Rajendiran L, et al. (2021). Reduced Angiopoietin-2 as a Predictive Biomarker for Clomiphene Citrate Resistance in Polycystic Ovary Syndrome. https://journals.lww.com/jhrs/fulltext/2021/14020/reduced_angiopoietin_2_as_a_predictive_biomarker.7.aspx ↩︎
  131. Abd-Elfattah A T, et al. (2019). Effect of Adding L-Carnitine to Clomiphene Resistant PCOs Women on the Ovulation and the Pregnancy Rate. https://ejhm.journals.ekb.eg/article_43079.html ↩︎
  132. Izhar R, et al. (2022). Effect of Administrating Coenzyme Q10 with Clomiphene Citrate on Ovulation Induction in Polycystic Ovary Syndrome Cases with Resistance to Clomiphene Citrate: A Randomized Controlled Trial. https://publish.kne-publishing.com/index.php/JRI/article/view/10008 ↩︎
  133. Guan H J, et al. (2021). Predictors of pregnancy after intrauterine insemination in women with polycystic ovary syndrome. https://journals.sagepub.com/doi/10.1177/03000605211018600 ↩︎
  134. Trop-Steinberg S, et al. (2023). Omega-3 Intake Improves Clinical Pregnancy Rate in Polycystic Ovary Syndrome Patients: A Double-Blind, Randomized Study. https://pubmed.ncbi.nlm.nih.gov/36841983/ ↩︎
  135. Mohammed W E, et al. (2022). Sildenafil citrate as an adjuvant to clomiphene citrate for ovulation induction in polycystic ovary syndrome: crossover randomized controlled trial. https://www.termedia.pl/Sildenafil-citrate-as-an-adjuvant-to-clomiphene-citrate-for-ovulation-induction-in-polycystic-ovary-syndrome-crossover-randomized-controlled-trial,4,46405,0,1.html ↩︎
  136. Diamond M P, et al. (2012). Endometrial Shedding Effect on Conception and Live Birth in Women With Polycystic Ovary Syndrome. https://journals.lww.com/greenjournal/abstract/2012/05000/endometrial_shedding_effect_on_conception_and_live.5.aspx ↩︎
  137. Dong X, et al. (2013). Does progesterone-induced endometrial withdrawal bleed before ovulation induction have negative effects on IUI outcomes in patients with polycystic ovary syndrome? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657371/ ↩︎
  138. Güngör N D and Güngör K, (2020). Ovarian stimulation drugs alter the metabolite content of the growing follicle: in vivo spectroscopic evaluation of follicle fluid. https://jtgga.org/articles/doi/jtgga.galenos.2020.2020.0104 ↩︎
  139. Peng Q, et al. (2023). Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1070264/full ↩︎
  140. Oróstica M L, et al. (2022). Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS. https://www.mdpi.com/1422-0067/23/7/3922 ↩︎
  141. Morley L C, et al. (2017). Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003053.pub6/full ↩︎
  142. Ibrahim M and Ahmeid M, (2020). Metformin effects on zonulin level in polycystic ovarian women. https://pub.iapchem.org/ojs/index.php/admet/article/view/905 ↩︎
  143. Tso L O, et al. (2020). Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006105.pub4/full ↩︎
  144. Zhou Z, et al. (2023). The effects of metformin on anti-Müllerian hormone levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis. https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-023-01195-1 ↩︎
  145. Molin J, et al. (2021). Gestational weight gain, appetite regulating hormones, and metformin treatment in polycystic ovary syndrome: A longitudinal, placebo-controlled study. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.17042 ↩︎
  146. Zhang Y, et al. (2017). Metformin Ameliorates Uterine Defects in a Rat Model of Polycystic Ovary Syndrome. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(17)30119-6/fulltext ↩︎
  147. Hu M, et al. (2020). TLR4-Associated IRF-7 and NFκB Signaling Act as a Molecular Link Between Androgen and Metformin Activities and Cytokine Synthesis in the PCOS Endometrium. https://academic.oup.com/jcem/article/106/4/e1022/6056640 ↩︎
  148. Liu Q, et al. (2014). Vitamin B12 Status in Metformin Treated Patients: Systematic Review. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0100379 ↩︎
  149. Janati S, et al. (2022). Changes of Serum Level of Homocysteine and Oxidative Stress Markers by Metformin and Inositol in Infertile Women with Polycystic Ovary Syndrome: A Double Blind Randomized Clinical Trial Study. https://www.ijfs.ir/article_245771.html ↩︎
  150. Schweighofer N, et al. (2014). Metformin Resistance Alleles in Polycystic Ovary Syndrome: Pattern and Association With Glucose Metabolism. https://www.tandfonline.com/doi/full/10.2217/pgs.13.223 ↩︎
  151. Kadhem A H, et al. (2023). Effects of KISS1 structural polymorphism on the risk of polycystic ovary syndrome and reproductive hormones in Iraqi women who take metformin. https://journals.sagepub.com/doi/10.1177/03000605231196837 ↩︎
  152. Nazirudeen R, et al. (2023). A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome. https://onlinelibrary.wiley.com/doi/10.1111/cen.14931 ↩︎
  153. Bahadur A, et al. (2021). Comparison of Clinical, Metabolic and Hormonal Effects of Metformin Versus Combined Therapy of Metformin With Myoinositol Plus D-Chiro-Inositol in Women With Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial. https://www.cureus.com/articles/61500-comparison-of-clinical-metabolic-and-hormonal-effects-of-metformin-versus-combined-therapy-of-metformin-with-myoinositol-plus-d-chiro-inositol-in-women-with-polycystic-ovary-syndrome-pcos-a-randomized-controlled-trial#!/ ↩︎
  154. Daneshjou D, et al. (2022). Sitagliptin/metformin improves the fertilization rate and embryo quality in polycystic ovary syndrome patients through increasing the expression of GDF9 and BMP15: A new alternative to metformin (a randomized trial). https://www.sciencedirect.com/science/article/abs/pii/S0165037822000286 ↩︎
  155. Kadoura S, et al. (2019). Effect of Calcium and Vitamin D Supplements as an Adjuvant Therapy to Metformin on Menstrual Cycle Abnormalities, Hormonal Profile, and IGF-1 System in Polycystic Ovary Syndrome Patients: A Randomized, Placebo-Controlled Clinical Trial. https://onlinelibrary.wiley.com/doi/10.1155/2019/9680390 ↩︎
  156. Tehrani H G, et al. (2014). The effect of calcium and vitamin D supplementation on menstrual cycle, body mass index and hyperandrogenism state of women with poly cystic ovarian syndrome. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268197/ ↩︎
  157. Sohrevardi S M, et al. (2021), Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial. https://link.springer.com/chapter/10.1007/978-3-030-64872-5_9 ↩︎
  158. Ali R, et al. (2023). An interplay of Progesterone, Leukemia Inhibitor Factor and Interleukin-6 in the window of implantation; Impact on fertility. https://www.sciencedirect.com/science/article/abs/pii/S1043466623002107 ↩︎
  159. Kicińska A M, et al. (2023). Successful Implementation of Menstrual Cycle Biomarkers in the Treatment of Infertility in Polycystic Ovary Syndrome—Case Report. https://www.mdpi.com/2227-9032/11/4/616 ↩︎
  160. Shirin S, et al. (2021). Cyclic Progesterone Therapy in Androgenic Polycystic Ovary Syndrome (PCOS)—A 6-Month Pilot Study of a Single Woman’s Experience Changes. https://www.mdpi.com/1648-9144/57/10/1024 ↩︎
  161. Briden L, et al. (2020). The central role of ovulatory disturbances in the etiology of androgenic polycystic ovary syndrome (PCOS)—Evidence for treatment with cyclic progesterone. https://www.sciencedirect.com/science/article/abs/pii/S1740675720300165 ↩︎
  162. Livadas S, et al. (2009). The effect of oral micronized progesterone on hormonal and metabolic parameters in anovulatory patients with polycystic ovary syndrome. https://www.fertstert.org/article/S0015-0282(09)00500-7/fulltext ↩︎
  163. Bagis T, et al. (2002). The Effects of Short-Term Medroxyprogesterone Acetate and Micronized Progesterone on Glucose Metabolism and Lipid Profiles in Patients with Polycystic Ovary Syndrome: A Prospective Randomized Study. https://academic.oup.com/jcem/article/87/10/4536/2846453 ↩︎
  164. Seckin B, et al. (2021). Comparison of two different starting doses of recombinant follicle stimulating hormone (rFSH) for intrauterine insemination (IUI) cycles in non-obese women with polycystic ovary syndrome (PCOS): a retrospective cohort study. https://www.tandfonline.com/doi/full/10.1080/01443615.2020.1849069 ↩︎
  165. Fischer D, et al. (2016). Avoiding OHSS: Controlled Ovarian Low-Dose Stimulation in Women with PCOS. https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0042-100206 ↩︎
  166. Homburg R and Howles C M, (1999). Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rational, results, reflections refinements. https://academic.oup.com/humupd/article/5/5/493/620371 ↩︎
  167. Si M, et al. (2023). Metabolic Syndrome Rather Than Other Phenotypes in PCOS as a Predictive Indicator for Clinical Outcomes in IVF: Comprehensive Phenotypic Assessment across All PCOS Classifications. https://www.mdpi.com/2077-0383/12/15/5073 ↩︎
  168. Song H, et al. (2022). Effect of ovulation before or after intrauterine insemination on pregnancy outcome in patients with unexplained infertility or polycystic ovarian syndrome. https://www.tandfonline.com/doi/full/10.1080/09513590.2022.2125952 ↩︎
  169. Firouz M, et al. (2020). Comparing the Effectiveness of Doing Intra-uterine Insemination 36 and 42 Hours after Human Chorionic Gonadotropin (HCG) Injection on Pregnancy Rate: A Randomized Clinical Trial. https://publish.kne-publishing.com/index.php/JFRH/article/view/4670 ↩︎
  170. Man Y, et al. (2020). The effect of different endometrial preparations on women with polycystic ovary syndrome undergoing initial frozen embryo transfer: A historical cohort analysis. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.14058 ↩︎
  171. Ozgur K, et al. (2024). Comparable ongoing pregnancy and pregnancy loss rates in natural cycle and artificial cycle frozen embryo transfers with intensive method-specific luteal phase support; a retrospective cohort study. https://www.sciencedirect.com/science/article/pii/S2468784724000758? ↩︎
  172. Su N J, et al. (2021). Association between baseline LH/FSH and live-birth rate after fresh-embryo transfer in polycystic ovary syndrome women. https://www.nature.com/articles/s41598-021-99850-4 ↩︎
  173. Chen C, et al. (2022). Luteinizing Hormone Suppression by Progestin-Primed Ovarian Stimulation Is Associated With Higher Implantation Rate for Patients With Polycystic Ovary Syndrome Who Underwent in vitro Fertilization/Intracytoplasmic Sperm Injection Cycles: Comparing With Short Protocol. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2021.744968/full ↩︎
  174. Zhou R, et al. (2023). Comparison of cumulative live birth rates between progestin-primed ovarian stimulation protocol and gonadotropin-releasing hormone antagonist protocol in different populations. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1117513/full ↩︎
  175. Cao Y, et al. (2021). Effect and Relationship of Seasons on the High Risk of Ovarian Hyperstimulation Syndrome After Oocyte Retrieval in Patients With Polycystic Ovary Syndrome. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.610828/full ↩︎
  176. Dopico X C, et al. (2015). Widespread seasonal gene expression reveals annual differences in human immunity and physiology. https://www.nature.com/articles/ncomms8000 ↩︎
  177. Wei L H, et al. 2013. The Role of IL-6 Trans-Signaling in Vascular Leakage: Implications for Ovarian Hyperstimulation Syndrome in a Murine Model. https://academic.oup.com/jcem/article/98/3/E472/2536905 ↩︎
  178. Thakre N and Homburg R, (2019). A review of IVF in PCOS patients at risk of ovarian hyperstimulation syndrome. https://www.tandfonline.com/doi/full/10.1080/17446651.2019.1631797 ↩︎
  179. Chen Z J, et al. (2016). Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. https://www.nejm.org/doi/10.1056/NEJMoa1513873 ↩︎
  180. Gilchrist R B, et al. (2023). A fresh start for IVM: capacitating the oocyte for development using pre-IVM. https://academic.oup.com/humupd/article-abstract/30/1/3/7252873 ↩︎
  181. Vuong L N, et al. (2024). Hormone-free vs. follicle-stimulating hormone-primed infertility treatment of women with polycystic ovary syndrome using biphasic in vitro maturation: a randomized controlled trial. https://www.sciencedirect.com/science/article/pii/S001502822402226X ↩︎
  182. Zhao F, et al. (2022). The feasibility of switching from IVF to IVM combined with all-blastocyst-culture and transfer for patients with ovarian hyperstimulation syndrome tendency. https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14160 ↩︎
  183. Yanagihara Y, et al. (2021). A modified GnRH antagonist method in combination with letrozole, cabergoline, and GnRH antagonist for PCOS: Safe and effective ovarian stimulation to treat PCOS and prevent OHSS. https://onlinelibrary.wiley.com/doi/10.1002/rmb2.12429 ↩︎
  184. Daghestani M H, et al. (2021). Adverse Effects of Selected Markers on the Metabolic and Endocrine Profiles of Obese Women With and Without PCOS. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.665446/full ↩︎
  185. Irani M, et al. (2017). Vitamin D Decreases Serum VEGF Correlating with Clinical Improvement in Vitamin D-Deficient Women with PCOS: A Randomized Placebo-Controlled Trial. https://www.mdpi.com/2072-6643/9/4/334 ↩︎
  186. Bordewijk E M, et al. (2019). Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001122.pub5/full ↩︎
  187. Turgut G D, et al. (2020). Comparison of the effects of bilateral and unilateral laparoscopic ovarian drilling on pregnancy rates in infertile patients with polycystic ovary syndrome. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/jog.14610 ↩︎
  188. Slouha E, et al. (2024). Ovarian Reserve and Hormone Alteration Following Laparoscopic Ovarian Drilling for Polycystic Ovarian Syndrome: A Systematic Review. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236422/ ↩︎
  189. Mohammad S M, (2023). The effect of laparoscopic ovarian drilling in patients with anovulatory polycystic ovary syndrome and high serum levels of anti-Müllerian hormone. https://medandlife.org/all-issues/2023/issue-7-2023/original-article-issue-7-2023/the-effect-of-laparoscopic-ovarian-drilling-in-patients-with-anovulatory-polycystic-ovary-syndrome-and-high-serum-levels-of-anti-mullerian-hormone/ ↩︎
  190. Ogawa S, et al. (2021). Decrease in serum anti-Müllerian hormone level per puncture with laparoscopic ovarian drilling using ultrasonically activated device. https://onlinelibrary.wiley.com/doi/10.1002/rmb2.12405 ↩︎
  191. Zhao Y, et al. (2024). Total weight loss rather than preoperative body mass index correlates with remission of irregular menstruation after sleeve gastrectomy in patients with polycystic ovary syndrome. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1355703/full ↩︎
  192. Huke C J, et al. (2024). The impact of obesity surgery on newborn anthropometrics in women with and without polycystic ovary syndrome. https://link.springer.com/article/10.1007/s00404-024-07593-0 ↩︎
  193. Samarasinghe S, et al. (2024). Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00538-5/fulltext ↩︎
  194. Ezzat R S, et al. (2021). Impact of bariatric surgery on androgen profile and ovarian volume in obese polycystic ovary syndrome patients with infertility. https://www.sciencedirect.com/science/article/pii/S1319562X21003909 ↩︎
  195. Casals G, et al. (2021). Bariatric Surgery on Reproductive Outcomes: the Impact According to the Diagnosis of Polycystic Ovarian Syndrome and Surgical Procedures. https://link.springer.com/article/10.1007/s11695-021-05297-x ↩︎
  196. Benito E, et al. (2020). Fertility and Pregnancy Outcomes in Women with Polycystic Ovary Syndrome Following Bariatric Surgery. https://academic.oup.com/jcem/article/105/9/e3384/5868099 ↩︎
  197. Shan Y, et al. (2023). The impact of metabolic surgery on natural conception rates in women with infertility, obesity and polycystic ovary syndrome: a retrospective study. https://www.soard.org/article/S1550-7289(23)00712-8/abstract ↩︎
  198. Liu J, et al. (2023). Double-edged sword: effects of human sperm reactive oxygen species on embryo development in IVF cycles. https://rbej.biomedcentral.com/articles/10.1186/s12958-022-01053-7 ↩︎

Share this post

Share on LinkedIn Share on Pinterest

fertilPEDIA

Questions or comments?